Generic Medicine Info
Indications and Dosage
Refractory partial seizures with or without secondary generalisation
Adult: In severe cases unresponsive to other drugs: As monotherapy: Initially, 1.2 g daily in 3 or 4 divided doses, may increase gradually by 0.6 g every 2 wk up to 2.4 g daily. May further increase if needed. Max: 3.6 g daily. As adjunctive treatment: Initially, 1.2 g daily in 3 or 4 divided doses, may increase by 1.2 g at wkly intervals up to 3.6 g daily. Reduce the dose of concomitant anticonvulsants by 20-33% when initiating felbamate therapy.
Child: As adjunct in Lennox-Gastaut syndrome: 2-<14 yr Initially, 15 mg/kg daily in 3 or 4 divided doses, may increase gradually in increments of 15 mg/kg at wkly intervals. Max: 45 mg/kg daily. Reduce the dose of concomitant anticonvulsants by 20% when initiating felbamate therapy; ≥14 yr Same as adult dose.
Renal Impairment
Reduce initial and maintenance doses by 50%.
Hepatic Impairment
History of blood disorders. Active liver disease or history of hepatic impairment.
Special Precautions
Avoid abrupt withdrawal. Renal impairment. Childn. Pregnancy and lactation.
Adverse Reactions
Nervous: Headache, dizziness, anorexia, insomnia, somnolence, anxiety.
GI: Nausea, vomiting, dyspepsia, constipation or diarrhoea.
Resp: Upper resp tract infection, rhinitis.
Hepatic: Increased SGPT.
Genitourinary: UTI, intramenstrual bleeding.
Ophthalmologic: Diplopia.
Otic: Otitis media.
Dermatologic: Photosensitivity, acne, rash, facial oedema.
Others: Fatigue, decreased wt, hypophosphataemia.
Potentially Fatal: Acute hepatic failure, aplastic anaemia.
Patient Counseling Information
Avoid exposure to UV radiation.
Monitoring Parameters
Perform CBC and LFT prior to and during treatment. Monitor for suicidality (e.g. depression, suicidal thoughts, mood/behavioural changes).
Drug Interactions
Enhanced metabolism w/ enzyme inducers (e.g. phenobarbital, carbamazepine, phenytoin). Prolonged half-life w/ gabapentin.
Description: Felbamate is a carbamate w/ unknown mechanism of action, but has properties similar to other anticonvulsants. It has weak inhibitory effects on GABA-receptor binding, benzodiazepine receptor binding, and is devoid of activity at the MK-801 receptor binding site of the NMDA receptor-ionophore complex.
Absorption: Well absorbed from the GI tract. Bioavailability: ≥80%. Time to peak plasma concentration: 1-6 hr.
Distribution: Enters breast milk. Volume of distribution: 0.76 L/kg. Plasma protein binding: Approx 22-25%, mainly to albumin.
Metabolism: Partly metabolised in the liver via hydroxylation and conjugation to inactive metabolites.
Excretion: Mainly via urine (40-50% as unchanged drug, 40% as inactive metabolites); faeces (<5%). Terminal elimination half-life: 16-23 hr.
Chemical Structure

Chemical Structure Image

Source: National Center for Biotechnology Information. PubChem Database. Felbamate, CID=3331, https://pubchem.ncbi.nlm.nih.gov/compound/Felbamate (accessed on Jan. 20, 2020)

Store between 20-25°C.
MIMS Class
ATC Classification
N03AX10 - felbamate ; Belongs to the class of other antiepileptics.
Anon. Felbamate. Lexicomp Online. Hudson, Ohio. Wolters Kluwer Clinical Drug Information, Inc. https://online.lexi.com. Accessed 20/02/2017.

Buckingham R (ed). Felbamate. Martindale: The Complete Drug Reference [online]. London. Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 20/02/2017.

Felbamate Tablet (Amneal Pharmaceuticals LLC). DailyMed. Source: U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/. Accessed 20/02/2017.

McEvoy GK, Snow EK, Miller J et al (eds). Felbamate. AHFS Drug Information (AHFS DI) [online]. American Society of Health-System Pharmacists (ASHP). https://www.medicinescomplete.com. Accessed 20/02/2017.

Disclaimer: This information is independently developed by MIMS based on Felbamate from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to MIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, MIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2022 MIMS. All rights reserved. Powered by MIMS.com
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in